Key Takeaways
Shanxi Securities maintained its "Buy-B" rating for Sansheng Pharmaceutical (01530.HK) after the company secured a global partnership with Pfizer including a $1.5 billion upfront payment.
"The company's 2025 performance will see high growth, benefiting from the SSGJ-707 authorization income," Shanxi Securities said in a report released May 7.
The rating is supported by the global collaboration agreement with Pfizer for Sansheng's core dual-antibody drug. While Shanxi Securities did not disclose a new price target, the report highlighted the company's strengthening pipeline, with several innovative drugs now entering the New Drug Application (NDA) stage.
The $1.5 billion upfront payment significantly strengthens Sansheng's financial position and validates its research and development capabilities. The company expects to enter a period of commercialization and sales growth beginning in 2026 as its pipeline matures.
The move signals growing confidence in Sansheng's pipeline and its ability to execute major global partnerships. Investors will be watching for further clinical updates and the successful filing of NDAs as the company moves toward commercializing its next wave of products.
This article is for informational purposes only and does not constitute investment advice.
